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Abstract:  35 
Hydrogen sulfide (H2S) has been shown to have powerful anti-oxidative and anti-36 
inflammatory properties which can regulate multiple cardiovascular functions. However, its 37 
precise role in diabetes-accelerated atherosclerosis remains unclear. We report here that H2S 38 
reduced aortic atherosclerotic plaque formation with reduction in superoxide (O2-) generation 39 
and the adhesion molecules in streptozotocin (STZ)-induced LDLr-/- mice but not in LDLr-/-40 
Nrf2-/- mice. In vitro, H2S inhibited foam cell formation, decreased O2- generation, as well as 41 
increased Nrf2 nuclear translocation and consequently heme oxygenase-1 (HO-1) expression 42 
up-regulation in high-glucose (HG) plus oxidized low density lipoprotein (ox-LDL)-treated 43 
primary peritoneal macrophages from wild-type but not Nrf2-/- mice. H2S also decreased O2- 44 
and adhesion molecules levels, increased Nrf2 nuclear translocation and HO-1 expression 45 
which were suppressed by Nrf2 knockdown in HG/ox-LDL-treated endothelial cells. H2S 46 
increased S-sulfhydration of Keapl, induced Nrf2 dissociation from Keap1, enhanced Nrf2 47 
nuclear translocation and inhibited O2- generation which were abrogated after Keapl mutated at 48 
Cys151, but not Cys273, in endothelial cells. Collectively, H2S attenuates diabetes-accelerated 49 
atherosclerosis, which may be related to inhibition of oxidative stress via Keap1 sulfhydrylation 50 
at Cys151 to activate Nrf2 signaling. This may provide a novel therapeutic target to prevent 51 
atherosclerosis in the context of diabetes.   52 
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Introduction: 53 
Diabetes leads to a marked increase in atherosclerosis (1). There is considerable evidence 54 
demonstrating that oxidative stress and inflammation are involved in the pathogenesis of 55 
diabetes and its complications, including atherosclerosis (2). It has been suggested that 56 
hyperglycemia-induced superoxide overproduction may be a key event in activation of 57 
pathways involved in the pathogenesis of diabetic complications (2). Approaches that limit 58 
oxidative stress may therefore translate to reduced inflammation and hence atherosclerosis.  59 
It is well established that nuclear factor erythoid 2–related factor 2 (Nrf2) is one of the most 60 
important cellular defense mechanisms against oxidative stress. Nrf2 is broadly expressed in 61 
tissues but is only activated in response to a range of oxidative and electrophilic stimuli (3). 62 
Upon oxidative stress, Nrf2 escapes Kelch-like ECH-associated protein 1 (Keap1)-mediated 63 
repression, translocates to the nucleus, binds to antioxidant response element (ARE), and 64 
induces the expression of a battery of antioxidant proteins, one of the most important of which 65 
is heme oxygenase 1 (HO-1) (4). Nrf2 has emerged as an important target in diabetes and related 66 
complications (5,6), and low dose dh404, which is an analogue of the Nrf2 agonist bardoxolone 67 
methyl, lowers oxidative stress and protects against diabetes-associated atherosclerosis (7). 68 
These studies suggest that augmentation of antioxidant defenses via up-regulation of the Nrf2 69 
pathway may be novel target for the prevention and treatment of diabetic complications.  70 
Hydrogen sulfide (H2S) plays an important role in physiology and pathophysiology in 71 
several biological systems. Emerging data suggest that H2S improves diabetic endothelial 72 
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dysfunction (8), nephropathy (9), retinopathy (10), and cardiomyopathy (11). However, there 73 
are no published data on the potential effect of H2S on accelerated atherosclerosis in diabetes.  74 
Some recent studies indicate that H2S is cytoprotective during myocardial ischemia-75 
reperfusion injury in the setting of diabetes by alleviating oxidative stress, and the ability of 76 
H2S to up-regulate cellular antioxidants in the heart in a Nrf2-dependent manner (12-14). H2S 77 
may therefore play an important role in diabetes-accelerated atherosclerosis, and the effects of 78 
H2S may be mediated via activation of Nrf2. In the present study, we have characterized 79 
whether and how H2S targets on Nrf2 against the development of diabetes-accelerated 80 
atherosclerosis. 81 
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Research design and Methods: 82 
1. Animals and treatment. 83 
LDLr-/- mice, on a C57BL/6 background, were purchased from Model Animal Research 84 
Center of Nanjing University. Nrf2-/- mice, on a C57BL/6 background, were a gift from 85 
Hongliang Li (Wuhan University), Nrf2-/- mice were crossed with LDLr-/- mice to obtain LDLr-86 
/-Nrf2-/-. At ages 8 weeks, male mice were rendered diabetic by administering 60 mg/kg/day 87 
streptozotocin (STZ) intraperitoneally (i.p.) daily for 5 days. After STZ administration, diabetic 88 
mice were administered the H2S donor GYY4137 (133 μmol/kg/day, i.p.) or vehicle, and kept 89 
on a high fat diet for 4 weeks. The dose of GYY4137 used was based on previous publications 90 
(15). Nondiabetic LDLr-/- or LDLr-/-Nrf2-/- mice were kept on a standard chow diet for 4 weeks 91 
as control. Mice were housed (n=1/cage, n=6/group) in metabolic cages for 48h prior to 92 
metabolic analysis to acclimatise. Body weight, food intake, water intake and urinary output 93 
were determined.  94 
All animal experiments were approved by the Committee on Animal Care of Nanjing 95 
Medical University, and were conducted according to the NIH Guidelines for the Care and Use 96 
of Laboratory Animals. All studies involving animals are reported in accordance with the 97 
ARRIVE guidelines. 98 
2. Blood sampling.  99 
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Plasma samples were obtained from 6-h–fasted mice. Glucose was measured directly from 100 
the tail tip with a glucometer; plasma lipid levels were measured enzymatically using 101 
commercial kits (Zhong Sheng Bei Kong, Peking, China) as the manufacturer’s instructions. 102 
3. Measurement of plasma H2S 103 
Plasma H2S concentration was measured as described previously (15).  104 
4. Analysis of Atherosclerotic Lesions 105 
To evaluate atherosclerotic lesions, en face whole and histological sections were used to 106 
analyze. The entire aorta attached to the heart was dissected and stained with Oil Red O (ORO; 107 
Sigma Aldrich, MO, USA) (16). Lesions within the sinus were visualized after staining with 108 
ORO as well as hematoxylin and eosin (HE) and quantitated as described previously (16).  109 
5. Cell culture and experimental conditions  110 
Mouse peritoneal macrophages were isolated from male C57BL/6 or Nrf2-/- mice as 111 
described previously (17). Peritoneal cells were collected by lavage and seeded in DMEM-low 112 
glucose medium (Gibco, Grand Island, USA) with 10% FBS (Gibco).  113 
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords 114 
according to a previously described method (18). The endothelial cells were cultured in 115 
Endothelial Cell Medium (ECM, ScienCell, CA, USA).  116 
EA.hy926 endothelial cells were purchased from the American Type Culture Collection 117 
(Rockville, MD, USA), and were cultured in DMEM-low glucose medium with 10% FBS. 118 
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 Confluent cells (80–85%) were incubated with D-glucose (25 mM, Sigma) plus ox-LDL 119 
(50 mg/L, Yiyuan biotechnology, China), in the absence or presence of GYY4137 (50, 100 120 
μM), sulfide-depleted GYY4137 (SDG, dissolved GYY4137 left unstoppered at room 121 
temperature for 5 days) or ZYJ1122 (a structural analogue of GYY4137 lacking sulfur) for 24 122 
h. 123 
6. Small interfering RNA or plasmid transfection 124 
EA.hy926 cells were transfected with siRNA oligonucleotide against Nrf2 (sense: 125 
5′AAGAGUAUGAGCUGGAAAAACdTdT-3′, antisense: 126 
5′GUUUUUCCAGCUCAUACAUUCdTdT-3′, Genepharma) or negative control siRNA. HO-127 
1 expression was silenced by HO-1 siRNA mix that was purchased from Santa Cruz. The 128 
plasmid pcDNA3-flag-Keap1 purchased from Addgene (Cambridge, MA) was termed as 129 
Keap1-WT. Single mutation at Cys-151, 273 or 288 to Ala (Haibio, Shanghai, China) was 130 
confirmed by DNA sequencing. EA.hy926 cells were transfected with expression vectors using 131 
the Lipofectamine 3000 reagent (Invitrogen). 132 
7. Foam Cell Formation Assay 133 
Macrophages were fixed with 4% paraformaldehyde and stained using 0.5% ORO. Images 134 
of cells were acquired using a light microscope (Nikon, Tokyo, Japan).    135 
8. Measurement of reactive oxygen species (ROS) formation  136 
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Superoxide production in tissue sections of upper descending thoracic aorta and cells was 137 
detected by dihydroethidium (DHE) assay as the manufacturer’s instructions. Briefly, cells or 138 
tissue were incubated with DHE for 30min. Fluorescence was measured with a Nikon TE2000 139 
Inverted Microscope and quantified using Image-Pro Plus analysis software. 140 
9. Immunofluorescence staining  141 
Sections or cells were fixed and permeabilized, then blocked and incubated with antibody 142 
against Nrf2, VCAM-1, ICAM-1, CD31, α-SMA or Macrophage (Abcam, Cambridge, MA). 143 
After additional washing, sections or cells were incubated with directly conjugated fluorescent 144 
secondary antibodies, and with DAPI (Invitrogen). Fluorescence was imaged using a Nikon 145 
TE2000 Inverted Microscope. Positive cells and total cells were quantified in 5 different 146 
sections from 6 different mice of each genotype, using Image-Pro Plus analysis software.   147 
10. RNA Analysis  148 
 HO-1, ICAM-1, VCAM-1, thioredoxin (Trx) and glutamate cysteine ligase catalytic 149 
subunit (GCLC) mRNA expression was quantified by real-time PCR (RT-PCR) with forward 150 
and reverse primers (Supplement Table 1). 151 
11. Isolation of Nuclear and Cytoplasmic Proteins and Western blotting  152 
Whole-cell, cytosolic and nuclear proteins were extracted using RIPA buffer (Sigma 153 
Aldrich) or a nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific Inc.). Western 154 
Blotting was performed as described previously (19). Primary antibodies included anti-Nrf2 155 
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(Santa Cruz, MO, UAS), anti-Nrf2 (phospho S40) (Abcam), anti-HO-1 (Bioworld Technology 156 
Inc., Nanjing, China), anti-VCAM-1 (Abcam), anti-ICAM-1 (Abcam), anti-histone H3 157 
(Bioworld), and anti-GAPDH (Abcam) antibody. Band intensities were analyzed using Image 158 
J 1.25 software. 159 
12. Immunoprecipitation 160 
The cells were harvested and lysed as previously described (20). Antibodies specific for 161 
Keap1 (Santa Cruz) or normal rabbit IgG were added to the supernatants followed by an 162 
incubation. Immune complexes were then precipitated with protein A-agarose beads. Bound 163 
proteins were eluted by boiling with loading buffer and analyzed by western blotting with anti-164 
Nrf2 antibody. 165 
13. “Tag-Switch” method  166 
Nrf2 and Keap1 S-sulfhydration (Keap1-SSH) was detected with “Tag-Switch” method 167 
(21). The protein of Keap1 was pulled down with immunoprecipitation, and treated with biotin-168 
linked cyanoacetate. Samples were resuspend in Laemmli buffer, heated, and subjected to 169 
western blotting analysis using anti-biotinantibody (Santa Cruz). 170 
Statistical analysis 171 
Data are expressed as mean ± standard error and were analyzed by one-way ANOVA 172 
followed by Newman-Keuls Multiple Comparison Test as appropriate. All statistical analyses 173 
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were performed using SPSS software, version 16.0. A value of P<0.05 was considered 174 
statistically significant. 175 
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Results: 176 
1. Metabolic characteristics and plasma level of H2S. 177 
As expected, diabetic LDLr-/- mice fed a HFD had lower body weight, higher plasma total 178 
cholesterol, triacylglycerol, urinary output, water intake and food intake when compared with 179 
those fed standard chow, and these effects were unaffected by treatment with GYY4137 180 
(Supplement Table2). Compared to LDLr-/- mice, plasma H2S concentration was reduced in 181 
HFD-fed diabetic LDLr-/- mice which could be significantly increased by administration of 182 
GYY4137 (Supplement Table2). 183 
2. H2S decreases Atherosclerotic Lesions in diabetic LDLr-/- mice.  184 
To determine the effect of H2S on the formation of atherosclerotic lesions in STZ-diabetic 185 
LDLr-/- mice, these animals were treated with GYY4137 or vehicle for 4 weeks, and a HFD 186 
diet was used to enhance atherogenesis (Figure 1A). Initially, we measured the total aortic 187 
lesion area between the proximal ascending aorta and the bifurcation of the iliac artery by en 188 
face analysis of ORO-stained aortas. As expected, diabetic mice showed an increase in 189 
atherosclerotic plaques compared with non-diabetic control. Treatment of diabetic LDLr-/- mice 190 
with H2S reduced lesion area (Figure 1B and Supplement Figure 1). Similar results were 191 
confirmed by HE and ORO staining in the aortic root (Figure 1C and 1D). Immunofluorescence 192 
analysis of sections from the aortic root revealed that macrophage content was increased in 193 
diabetic LDLr-/- mice, and this effect was attenuated by H2S treatment (Figure 1E and 1F). 194 
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Collectively, these data demonstrate that exogenous H2S decreases atherosclerotic lesions in 195 
diabetic LDLr-/- mice.  196 
3. H2S reduces the level of superoxide, VCAM-1 and ICAM-1, and activates expression of 197 
Nrf2 and associated antioxidant proteins, in vessels of diabetic LDLr-/- mice. 198 
Oxidative stress plays an important role in the pathogenesis of diabetes and its 199 
complications. To determine whether the protective role of H2S in atherosclerotic lesions might 200 
relate to reduction of ROS, we measured aortic superoxide formation by DHE assay. As 201 
expected, compared with non-diabetic LDLr-/- mice, endothelial fluorescence was increased in 202 
diabetic LDLr-/- mice. In contrast, endothelial superoxide production in diabetic LDLr-/- mice 203 
was attenuated following GYY4137 administration (Figure 2A and 2B). Several recent studies 204 
have identified Nrf2 as a critical transcription factor that regulates a battery of antioxidant genes 205 
in the face of oxidative stress (3). Recent work has also shown that H2S regulates Nrf2 in 206 
myocardial tissue (12). To examine whether Nrf2 is activated in response to H2S treatment, we 207 
investigated the intracellular localization of Nrf2. Immunofluorescence microscopy showed 208 
enhanced nuclear staining of Nrf2 in aortas of H2S-treated in comparison to untreated diabetic 209 
LDLr-/- mice (Figure 2C). To further confirm the Nrf2 localization, we performed double 210 
staining for Nrf2 and CD31 (endothelial marker), α-SMA (smooth muscle cells marker) or 211 
macrophages marker and found Nrf2 could be clearly shown co-localized with three markers 212 
in aorta. And GYY4137 treatment increased Nrf2 nuclear translocation in aortic endothelial 213 
cells, smooth muscle cells and macrophages (Supplement Figure 2). In addition, the induction 214 
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of expression of the Nrf2-related antioxidant defense enzyme HO-1 was substantially increased 215 
by H2S (Figure 2D); whilst other Nrf2 target genes, such as Trx and GCLC, were unchanged 216 
(Supplement Figure 3).  217 
Oxidative stress induces the expression of adhesion molecules such as VCAM-1 and 218 
ICAM-1, which promote the recruitment to, and accumulation of inflammatory cells within the 219 
developing atherosclerotic lesion. Therefore, the levels of VCAM-1 and ICAM-1 in aorta were 220 
determined by RT-PCR and immunofluorescence, after 4 weeks on HFD, both VCAM-1 and 221 
ICAM-1 increased in diabetic LDLr-/- mice, and this effect was abrogated by treatment with 222 
H2S (Figure 2E-2G and Supplement Figure 4). Together, these results indicate that exogenous 223 
H2S attenuates diabetes-accelerated atherosclerosis, most likely by maintaining redox balance 224 
via the Nrf2 pathway.  225 
4. Nrf2 deficiency abolishes the protective effects of H2S in STZ-induced LDLr-/- mice. 226 
To further explore the pathophysiological significance of H2S-induced Nrf2 activation in 227 
vivo, we mated LDLr-/- mice with Nrf2-/- mice to generate LDLr-/-Nrf2-/- mice. After injection of 228 
STZ and 4 weeks of HFD, with or without concomitant GYY4137 treatment, metabolic 229 
characteristics were assessed (Supplement Table 3). Histological assessment of atherosclerotic 230 
lesions at the aortic sinus by ORO and HE staining showed a marked increase of plaques in the 231 
aortic root from LDLr-/-Nrf2-/- diabetic mice fed HFD, and the aortic plaque area was now not 232 
reduced by H2S treatment (Figure 3A and 3B).  Moreover, the expression of superoxide, 233 
VCAM-1, and ICAM-1 were not reduced after treatment of GYY4137 in diabetic LDLr-/-Nrf2-234 
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/- mice (Figure 3C-G and Supplement Figure 5). Complementary analyses of Nrf2 target gene 235 
levels in aorta revealed that the expression of HO-1 could not be augmented by H2S in the 236 
presence of Nrf2 deficiency (Figure 3H). These results demonstrate that Nrf2 is necessary for 237 
the inhibitory effect of H2S to be exerted on diabetes-accelerated atherosclerosis in vivo. 238 
5. H2S decreases foam cell formation and production of superoxide, and enhances HO-1 239 
expression via activation of Nrf2, in HG plus ox-LDL treated mouse macrophages. 240 
Accumulation of cholesterol and cholesteryl esters in macrophages and subsequent foam 241 
cell formation is a critical early event in atherogenesis. To further investigate the molecular 242 
mechanisms underlying the effects of H2S, we established a macrophage model in 243 
hyperglycaemic and hyperlipidemic conditions in vitro, which replicates some of the 244 
characteristics of macrophages in the diabetes-accelerated atherosclerotic mouse model. Mouse 245 
peritoneal macrophages from C57BL/6 were incubated with HG plus ox-LDL, with or without 246 
GYY4137 for 24 h; following which foam cell formation and ROS production were measured 247 
by ORO staining and DHE assay respectively. As expected, foam cell formation was induced 248 
in macrophages exposed to ox-LDL, and this effect was exaggerated by co-incubation with HG 249 
(data not shown). Pretreatment with GYY4137 (50 or 100 μM), but not SDG or ZYJ1122, 250 
abrogated this effect (Figure 4A and Supplement Figure 6). In addition, superoxide generation 251 
was enhanced in HG plus ox-LDL-stimulated macrophages (Figure 4B and 4C), and this too 252 
was attenuated by pretreatment with H2S.  253 
 16 
   
Next, to test whether Nrf2 is involved in the effects of H2S on macrophage function, we 254 
investigated its intracellular localization. Immunofluorescence microscopy showed enhanced 255 
nuclear staining of Nrf2 in cells treated with H2S in comparison to vehicle-treated cells, in the 256 
presence of HG plus ox-LDL (Figure 4D). Western blotting analysis of cytoplasmic and nuclear 257 
protein extracts also indicated increased nuclear accumulation of Nrf2 protein in cells treated 258 
with H2S (Figure 4E and 4F), suggesting that Nrf2 is activated in response to H2S exposure. 259 
Similarly, in the presence of HG plus ox-LDL, H2S-pretreated macrophages exhibited increased 260 
production of HO-1 (Figure 4G).  261 
Additional experiments were performed to confirm the involvement of Nrf2 in the 262 
protective effect of H2S, using mouse peritoneal macrophages isolated from Nrf2-/- mice. 263 
Inhibition of foam cell formation and superoxide generation induced by HG plus ox-LDL was 264 
attenuated by H2S treatment in Nrf2 knockout (KO) cells (Figure 5A-5C). Consistent with these 265 
results, elevation of HO-1 expression by H2S treatment was also abolished in the Nrf2 KO 266 
group (Figure 5D). Furthermore, HO-1 knockdown by siRNA or inhibition by ZnPP (HO-1 267 
inhibitor) also abrogated H2S-mediated suppression of O2- generation and foam cell formation 268 
(Supplement Figure 7). These results demonstrate that Nrf2/HO-1 pathway is responsible for 269 
the inhibitory effects of H2S on HG plus ox-LDL-induced foam cell formation and oxidative 270 
stress in macrophages. 271 
6. H2S decreases ROS, ICAM-1 and VCAM-1 generation, and enhances HO-1 expression 272 
via Nrf2 signaling, in HG plus ox-LDL treated endothelial cells. 273 
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It has been reported that endothelial dysfunction caused by lipotoxicity or hyperglycemia 274 
is mediated through several mechanisms including increased oxidative stress and 275 
proinflammatory responses. Therefore, we measured the effect of H2S on oxidative stress in 276 
endothelial cells by DHE assay. Stimulation of HUVECs with HG plus ox-LDL for 24 h caused 277 
an increase in production of superoxide, and this increase was alleviated by pretreatment with 278 
GYY4137 (50 or 100 μM) (Figure 6A and 6B) but not with SDG or ZYJ1122 (Supplement 279 
Figure 8). 280 
To confirm whether the cytoprotective effect of H2S against oxidative stress was also 281 
associated with Nrf2, we carried out immunofluorescence and western blotting for Nrf2. 282 
GYY4137 had no effect on Nrf2 phosphorylation, but can increase the Nrf2 protein expression 283 
in the nuclear in HG plus ox-LDL-stimulated endothelial cells (Figure 6C-E and Supplement 284 
Figure 9A), implying that H2S may promote phosphorylation-independent Nrf2 nuclear 285 
translocation. Consistent with our in vivo study, H2S reduced the expression of VCAM-1 and 286 
ICAM-1 (Figure 6F and 6G); in addition, the Nrf2 target gene HO-1 was also increased by H2S 287 
pretreatment (Figure 6H and 6I). To further clarify whether H2S-induced down-regulation of 288 
oxidative stress was dependent on activation of the Nrf2 pathway, EA.hy926 cells were 289 
transfected Nrf2 siRNA for 24 h before H2S and HG+ox-LDL treatment. Western blotting 290 
revealed that individual transfection with Nrf2 siRNA successfully reduced Nrf2 protein 291 
expression at 24 h post-transfection, as compared to negative control siRNA-transfected (Ctl 292 
siRNA) cells (Figure 7A). Nrf2 knockdown abrogated H2S-mediated suppression of ROS 293 
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production induced by HG plus ox-LDL in endothelial cells (Figure 7B and 7C). Furthermore, 294 
inhibition of HO-1 expression or activity by siRNA or ZnPP abolished the protective effects of 295 
H2S (Supplement Figure 10). Together, these results indicate that the anti-oxidative and anti-296 
inflammatory effects of H2S in the presence of HG plus ox-LDL are partially mediated by 297 
Nrf2/HO-1 pathway in endothelial cells.   298 
7. H2S S-sulfhydrylated Keapl at Cys151 to regulate Nrf2 activity and reduce ROS 299 
generation in HG plus ox-LDL treated endothelial cells. 300 
Generally, Nrf2 is retained in an unactivated state binding with Keap1 in the cytoplasm, 301 
which serves as an adaptor for the degradation of Nrf2. Nrf2 can be activated by physiological 302 
stimuli which disrupt Keap1-Nrf2 interactions leading to nuclear translocation of Nrf2 (22). To 303 
further explore the mechanisms of Nrf2 activation, we immunoprecipitated the cell lysate using 304 
an anti-Keap1 antibody and blotted for Nrf2. The results showed that GYY4137 decreased 305 
Nrf2/Keap1 interaction in HG plus ox-LDL-treated endothelial cells (Figure 8A). S-306 
sulfhydration, the addition of one sulfhydryl to thiol side of cysteine residue and formation of 307 
persulfide group (R-S-S-H), has been identified as a novel post-translational modification by 308 
H2S in eukaryotic cells. However, the covalent modification in sulfhydration is reversed by 309 
reducing agents, such as dithiothreitol (DTT) (23). We tested the S-sulfhydration of Nrf2 and 310 
found that H2S donor GYY4137 or NaHS had no effect on Nrf2 S-sulfhydration (Supplement 311 
Figure 9B).We next investigated whether H2S directly modified Keapl. After preincubation 312 
with GYY4137, EA.hy926 cells were treated with HG plus ox-LDL and subjected to “Tag-313 
 19 
   
Switch” assay. There was stronger S-sulfhydration of Keap1 after GYY4137 incubation (Figure 314 
8B). To identify the S-sulfhydrated cysteine residue, Keap1 mutated at Cys151, Cys273, or 315 
Cys288 to alanine (C151A, C273A, or C288A) or wild-type (WT) was transfected into 316 
endothelial cells. H2S still enhanced S-sulfhydration on Keap1 after wild-type or mutated 317 
Keap1 at Cys288 but not at Cys151 and Cys273 overexpression (Figure 8C). H2S increased 318 
Nrf2 dissociation from Keap1 in HG plus ox-LDL-treated endothelial cells after Keap1-WT 319 
and Keap1-C273A but not Keap1-C151A overexpression (Figure 8D). Moreover, after Keap1 320 
mutation at Cys151, H2S failed to induce Nrf2 nuclear translocation or decrease the generation 321 
of superoxide (Figure 8E-G). These findings indicate that S-sulfhydration of Cys151 in Keap1 322 
is critical for Nrf2 activation in HG plus ox-LDL treated endothelial cells.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               323 
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Discussion: 324 
A complex interaction between inflammation, lipid deposition, monocytic infiltration and 325 
endothelial dysfunction is responsible for the initiation and progression of diabetes-accelerated 326 
atherosclerosis (1). Experimental evidence for an anti-atherosclerotic effect of H2S has been 327 
obtained in numerous studies in hyperlipidemic animal and cell models (15, 24-26), but the 328 
anti-atherosclerotic effect in the context of diabetes has not been previously investigated. 329 
Recent data published by our group demonstrated that treatment with H2S decreased aortic 330 
atherosclerotic plaque formation and partially restored aortic endothelium-dependent relaxation 331 
in ApoE-/- mice fed with a HFD (15). Exogenous H2S improved endothelium-dependent 332 
relaxation in isolated vascular rings incubated with high glucose, and attenuated 333 
hyperglycemia-induced DNA injury and improved cellular viability in bEnd.3 microvascular 334 
endothelial cells (8). These data suggested that exogenous H2S might serve as a treatment option 335 
for diabetic-associated atherosclerosis. Indeed, in the present study, we found that H2S 336 
supplementation reduces lesion area and macrophage infiltration in diabetic LDLr-/- mice. In 337 
agreement with these findings, we also observed that H2S treatment attenuated HG+ox-LDL-338 
induced foam cell formation. Our study provides the first evidence that H2S may prevent 339 
development of diabetes-accelerated atherosclerosis, and that this does not relate to any effects 340 
on circulating blood glucose or cholesterol.  341 
Several pathological mechanisms have been proposed for diabetic vascular complications, 342 
including diabetes-accelerated atherosclerosis, such as increased polyol pathway flux, 343 
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increased advanced glycation end-product formation and activation of protein kinase C; all of 344 
these, in association with hyperglycemia-induced ROS accumulation (27). Endothelial cells 345 
and macrophages are both sources of ROS. Indeed, in our study, we have demonstrated that 346 
STZ-treated LDLr-/- mice fed a HFD showed an increase in atherosclerotic plaques compared 347 
with non-diabetic LDLr-/- mice, accompanied by increased superoxide production in aorta and 348 
this was further confirmed in HG plus ox-LDL-treated macrophages and endothelial cells. The 349 
increase in ROS promotes the recruitment and accumulation of inflammatory cells to the 350 
developing atherosclerotic lesion. H2S has also been shown to have powerful antioxidant 351 
properties. Exogenous H2S attenuates the hyperglycemia-induced enhancement of ROS 352 
formation in endothelial cells and human U937 monocytes (8,28). In line with these findings, 353 
we observed that H2S decreased superoxide generation in macrophages and endothelial cells 354 
cultured with HG plus ox-LDL. Furthermore, we showed that superoxide production in the 355 
aortas of diabetic LDLr-/- mice was reduced following H2S administration. In this study, we 356 
show for the first time that inhibition of HG+ox-LDL-generated ROS with H2S prevents the 357 
diabetes-induced increase in plaque area. Additionally, we found that H2S attenuates the 358 
increase in aortic VCAM-1 and ICAM-1 expression.  359 
Recent studies indicate that H2S may up-regulate endogenous antioxidants through an Nrf2-360 
dependent signaling pathway (12) to combat oxidative stress. To date, the role of Nrf2 in 361 
atherosclerosis remains controversial. Myeloid Nrf2 deficiency aggravates both early and late 362 
stages of atherosclerosis in LDLr-/- mice (29,30). Ellagic acid improves oxidant-induced 363 
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endothelial dysfunction and atherosclerosis partly via Nrf2 activation (31). In contrast to these 364 
reported protective actions, Nrf2 has also been ascribed as having potentially pro-atherogenic 365 
functions, in that ApoE-/-Nrf2-/- double knockout mice exhibited reduced plaque (32). In 366 
diabetes-associated atherosclerosis, a novel analog of the Nrf2 agonist bardoxolone methyl, has 367 
been found to reduce atherosclerotic lesions as well as oxidative stress and the proinflammatory 368 
mediators ICAM-1 and VCAM-1, in STZ-induced diabetic ApoE-/- mice (7). Our data support 369 
previous findings as regards the protective actions of Nrf2, and suggest that H2S can attenuate 370 
endothelial dysfunction, foam cell formation and atherosclerosis in the context of diabetes, at 371 
least partially via the Nrf2/HO-1 pathway. 372 
A widely accepted model for Nrf2 nuclear accumulation describes that a modification of 373 
the Keap1 cysteines leads directly to the dissociation of the Keap1-Nrf2 complex (33). Recently, 374 
one study suggested that Keap1 can be S-sulfhydrated at Cys151 which stimulates the 375 
dissociation of Nrf2 to enable its translocation to nucleus (34). We found that Keap1 could be 376 
S-sulfhydrated at Cys151 and Cys273 simultaneously, but only the S-sulfhydration of Cys151 377 
was involved in activation of Nrf2 which decreased the ROS generation to improve endothelial 378 
function. Kim S et al. found that thiol modification of Keap1 Cys288 is responsible for daillyl 379 
trisulfide-induced activation of Nrf2 signaling (35). However, in our study, Cys288 of Keap1 380 
could not be S-sulfhydrated after treatment with GYY4137. This discrepancy may be attributed 381 
to different regulatory mechanisms in different cell types, the use of different H2S treatment 382 
regiments giving rise to different kinetics of H2S release. Nevertheless, this study demonstrates 383 
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a significant role of Keap1 Cys151 S-sulfhydration in the protective effects of H2S against 384 
diabetes-accelerated atherosclerosis. 385 
In summary, our study provided definitive evidence that H2S can lessen diabetes-386 
accelerated atherosclerosis in LDLr-/- mice and improve hyperglycemia/ox-LDL-induced injury 387 
in macrophages and endothelial cells. This protective effect of H2S can partly be attributed to 388 
activation of Nrf2 via Keap1 S-sulfhydration at Cys151. Our findings suggest that activation of 389 
Nrf2 may be a potential novel therapeutic strategy against diabetes-associated vascular disease, 390 
and that exogenous H2S administration in the form of an H2S donor GYY4137 may be of 391 
therapeutic benefit in the setting of diabetes-associated atherosclerosis. Finally, our study 392 
provides new insight into the mechanisms responsible for the anti-atherosclerotic effects of H2S 393 
in the context of diabetes.  394 
 24 
   
Author Contributions. 395 
L.X. and Y.G. researched data, contributed to discussion, and edited the manuscript. W.M., 396 
S.Z., W.W. and Y.M. researched data. G.M. contributed to discussion and proof-read the 397 
manuscript. H.F., Y.H., and Y.W. researched data. G.L. designed study and reviewed data. 398 
P.K.M., X.W., H.W., Z.Z. and Y.Y. reviewed the manuscript. A.F. contributed to discussion 399 
and re-wrote the manuscript. Z.H. reviewed data and edited the manuscript. Y.J. designed study, 400 
reviewed data and edited manuscript. All authors have approved the final version of the 401 
manuscript. Prof. Y.J. is the guarantor of this work and, as such, had full access to all the data 402 
in the study and takes responsibility for the integrity of the data and the accuracy of the data 403 
analysis. 404 
Acknowledgments 405 
We gratefully acknowledge Prof. Hongliang Li (Renmin Hospital of Wuhan University, Wuhan 406 
University) to offer the Nrf2-/- mice. This work was supported by grants from the National 407 
Natural Science Foundation of China (grant nos. 81200197, 81170083, 81330004), the National 408 
Basic Research Program of China (973) (grant no 2011CB503903, 2012CB517803). The 409 
authors declare no financial conflict of interest that might be construed to influence the results 410 
or interpretation of their manuscript. 411 
  412 
 413 
 25 
   
References: 414 
 1. Eckel RH, Wassef M, Chait A, Sobel B, Barrett E, King G, Lopes-Virella M, Reusch J, 415 
Ruderman N, Steiner G, Vlassara H: Prevention Conference VI: Diabetes and Cardiovascular 416 
Disease: Writing Group II:  pathogenesis of atherosclerosis in diabetes. Circulation 105:e138-417 
e143, 2002 418 
 2. Forbes JM, Cooper ME: Mechanisms of diabetic complications. Physiol Rev 93:137-188, 419 
2013 420 
 3. Ma Q: Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 53:401-421 
426, 2013 422 
 4. Niture SK, Khatri R, Jaiswal AK: Regulation of Nrf2-an update. Free Radic Biol Med 423 
66:36-44, 2014 424 
 5. Xu X, Luo P, Wang Y, Cui Y, Miao L: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) 425 
is a novel therapeutic target for diabetic complications. J Int Med Res 41:13-19, 2013 426 
 6. Ramprasath T, Selvam GS: Potential impact of genetic variants in Nrf2 regulated 427 
antioxidant genes and risk prediction of diabetes and associated cardiac complications. Curr 428 
Med Chem 20:4680-4693, 2013 429 
 7. Tan SM, Sharma A, Stefanovic N, Yuen DY, Karagiannis TC, Meyer C, Ward KW, Cooper 430 
ME, de Haan JB: Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent 431 
manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. 432 
Diabetes 63:3091-3103, 2014 433 
 8. Suzuki K, Olah G, Modis K, Coletta C, Kulp G, Gero D, Szoleczky P, Chang T, Zhou Z, 434 
Wu L, Wang R, Papapetropoulos A, Szabo C: Hydrogen sulfide replacement therapy protects 435 
the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl 436 
Acad Sci U S A 108:13829-13834, 2011 437 
 9. Zhou X, Feng Y, Zhan Z, Chen J: Hydrogen sulfide alleviates diabetic nephropathy in a 438 
streptozotocin-induced diabetic rat model. J Biol Chem 289:28827-28834, 2014 439 
10. Si YF, Wang J, Guan J, Zhou L, Sheng Y, Zhao J: Treatment with hydrogen sulfide 440 
alleviates streptozotocin-induced diabetic retinopathy in rats. Br J Pharmacol 169:619-631, 441 
2013 442 
11. Zhou X, An G, Lu X: Hydrogen sulfide attenuates the development of diabetic 443 
cardiomyopathy. Clin Sci (Lond) 128:325-335, 2015 444 
12. Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer 445 
DJ: Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105:365-374, 446 
 26 
   
2009 447 
13. Peake BF, Nicholson CK, Lambert JP, Hood RL, Amin H, Amin S, Calvert JW: Hydrogen 448 
sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by 449 
activating Nrf2 signaling in an Erk-dependent manner. Am J Physiol Heart Circ Physiol 450 
304:H1215-H1224, 2013 451 
14. Zhou X, An G, Chen J: Inhibitory effects of hydrogen sulphide on pulmonary fibrosis in 452 
smoking rats via attenuation of oxidative stress and inflammation. J Cell Mol Med 18:1098-453 
1103, 2014 454 
15. Liu Z, Han Y, Li L, Lu H, Meng G, Li X, Shirhan M, Peh MT, Xie L, Zhou S, Wang X, 455 
Chen Q, Dai W, Tan CH, Pan S, Moore PK, Ji Y: The hydrogen sulfide donor, GYY4137, 456 
exhibits anti-atherosclerotic activity in high fat fed apolipoprotein E(-/-) mice. Br J Pharmacol 457 
169:1795-1809, 2013 458 
16. Cheng WL, Wang PX, Wang T, Zhang Y, Du C, Li H, Ji Y: Regulator of G-protein 459 
signalling 5 protects against atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol, 460 
2014 461 
17. Mauldin JP, Srinivasan S, Mulya A, Gebre A, Parks JS, Daugherty A, Hedrick CC: 462 
Reduction in ABCG1 in Type 2 diabetic mice increases macrophage foam cell formation. J 463 
Biol Chem 281:21216-21224, 2006 464 
18. Ferro A, Queen LR, Priest RM, Xu B, Ritter JM, Poston L, Ward JP: Activation of nitric 465 
oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br J 466 
Pharmacol 126:1872-1880, 1999 467 
19. Xie L, Liu Z, Lu H, Zhang W, Mi Q, Li X, Tang Y, Chen Q, Ferro A, Ji Y: Pyridoxine 468 
inhibits endothelial NOS uncoupling induced by oxidized low-density lipoprotein via the 469 
PKCalpha signalling pathway in human umbilical vein endothelial cells. Br J Pharmacol 470 
165:754-764, 2012 471 
20. Mi Q, Chen N, Shaifta Y, Xie L, Lu H, Liu Z, Chen Q, Hamid C, Becker S, Ji Y, Ferro A: 472 
Activation of endothelial nitric oxide synthase is dependent on its interaction with globular 473 
actin in human umbilical vein endothelial cells. J Mol Cell Cardiol 51:419-427, 2011 474 
21. Park CM, Macinkovic I, Filipovic MR, Xian M: Use of the "tag-switch" method for the 475 
detection of protein S-sulfhydration. Methods Enzymol 555:39-56, 2015 476 
22. Zhang DD, Lo SC, Sun Z, Habib GM, Lieberman MW, Hannink M: Ubiquitination of 477 
Keap1, a BTB-Kelch substrate adaptor protein for Cul3, targets  Keap1 for degradation by a 478 
proteasome-independent pathway. J Biol Chem 280:30091-30099, 2005 479 
 27 
   
23. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, Barrow RK, Yang G, Wang R, 480 
Snyder SH: H2S signals through protein S-sulfhydration. Sci Signal 2:a72, 2009 481 
24. Mani S, Li H, Untereiner A, Wu L, Yang G, Austin RC, Dickhout JG, Lhotak S, Meng QH, 482 
Wang R: Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. 483 
Circulation 127:2523-2534, 2013 484 
25. Wang XH, Wang F, You SJ, Cao YJ, Cao LD, Han Q, Liu CF, Hu LF: Dysregulation of 485 
cystathionine gamma-lyase (CSE)/hydrogen sulfide pathway contributes to ox-LDL-induced 486 
inflammation in macrophage. Cell Signal 25:2255-2262, 2013 487 
26. Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, Tang X, Ren Y, Tang C, Du J: Role of 488 
hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout 489 
mice. Arterioscler Thromb Vasc Biol 29:173-179, 2009 490 
27. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 491 
414:813-820, 2001 492 
28. Manna P, Jain SK: L-cysteine and hydrogen sulfide increase PIP3 and AMPK/PPARgamma 493 
expression and decrease ROS and vascular inflammation markers in high glucose treated 494 
human U937 monocytes. J Cell Biochem 114:2334-2345, 2013 495 
29. Collins AR, Gupte AA, Ji R, Ramirez MR, Minze LJ, Liu JZ, Arredondo M, Ren Y, Deng 496 
T, Wang J, Lyon CJ, Hsueh WA: Myeloid deletion of nuclear factor erythroid 2-related factor 497 
2 increases atherosclerosis and liver injury. Arterioscler Thromb Vasc Biol 32:2839-2846, 2012 498 
30. Ruotsalainen AK, Inkala M, Partanen ME, Lappalainen JP, Kansanen E, Makinen PI, 499 
Heinonen SE, Laitinen HM, Heikkila J, Vatanen T, Horkko S, Yamamoto M, Yla-Herttuala S, 500 
Jauhiainen M, Levonen AL: The absence of macrophage Nrf2 promotes early atherogenesis. 501 
Cardiovasc Res 98:107-115, 2013 502 
31. Ding Y, Zhang B, Zhou K, Chen M, Wang M, Jia Y, Song Y, Li Y, Wen A: Dietary ellagic 503 
acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of Nrf2 504 
activation. Int J Cardiol 175:508-514, 2014 505 
32. Barajas B, Che N, Yin F, Rowshanrad A, Orozco LD, Gong KW, Wang X, Castellani LW, 506 
Reue K, Lusis AJ, Araujo JA: NF-E2-related factor 2 promotes atherosclerosis by effects on 507 
plasma lipoproteins and cholesterol transport that overshadow antioxidant protection. 508 
Arterioscler Thromb Vasc Biol 31:58-66, 2011 509 
33. Holland R, Fishbein JC: Chemistry of the cysteine sensors in Kelch-like ECH-associated 510 
protein 1. Antioxid Redox Signal 13:1749-1761, 2010 511 
34. Yang G, Zhao K, Ju Y, Mani S, Cao Q, Puukila S, Khaper N, Wu L, Wang R: Hydrogen 512 
 28 
   
sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. 513 
Antioxid Redox Signal 18:1906-1919, 2013 514 
35. Kim S, Lee HG, Park SA, Kundu JK, Keum YS, Cha YN, Na HK, Surh YJ: Keap1 cysteine 515 
288 as a potential target for diallyl trisulfide-induced Nrf2 activation. PLoS One 9:e85984, 2014 516 
  517 
 518 
 29 
   
Figure Legends      519 
Figure 1. Effects of H2S on atherosclerosis in HFD fed diabetic LDLr-/- mice. Diabetic 520 
LDLr-/- mice were fed a high-fat diet (HFD) and received daily ip injection of saline or H2S 521 
donor GYY4137 (133 μmol/kg/day) for 4 weeks. A, Schema of experimental procedure. B, 522 
Lesion areas shown was quantified using Oil-Red O (ORO) staining of the thoracoabdominal 523 
aorta. C and D, Representative ORO and hematoxylin eosin (HE)-stained images and 524 
quantification of aortic sinus sections from LDLr-/- (n=6), STZ+HFD (n=9) and 525 
STZ+HFD+GYY4137 (n=8). Scale bars, 200 μm. E and F, Frozen sections of aortic root were 526 
stained for anti-macrophage (green) and DAPI (blue). Dotted lines indicate the boundary of 527 
lesion and aortic tunica intima. L indicates lumen. Quantitative data in the graph represent the 528 
positively stained area percentage of plaque (n=6). Scale bars, 100 μm. Data shown are 529 
mean±SEM. ***P<0.001 vs. LDLr-/- mice. ###P<0.001 vs. STZ+HFD mice.  530 
Figure 2. Effects of H2S on ROS formation, Nrf2, VCAM-1 and ICAM-1 expression in 531 
aortas from HFD fed diabetic LDLr-/- mice. A, Representative dihydroethidium (DHE) 532 
fluorescence image of aortic tissue from LDLr-/-, STZ+HFD and STZ+HFD+GYY4137. Scale 533 
bars, 100 μm. B, Quantification of DHE fluorescence image of A, ***P<0.001 vs. LDLr-/- mice. 534 
##P<0.01 vs. STZ+HFD mice, n=6. C, Representative immunostaining for Nrf2 (green) and 535 
DAPI (blue) of aorta. Scale bars, 50 μm. D, mRNA levels of HO-1 in the aortas of LDLr-/- (n=6), 536 
STZ+HFD (n=6) and STZ+HFD+GYY4137 (n=8), as determined by real-time quantitative 537 
polymerase chain reaction (RT-PCR) analysis. E and F, mRNA levels of VCAM-1 and ICAM-538 
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1 in the aortas of LDLr-/- (n=6), STZ+HFD (n=6) and STZ+HFD+GYY4137 (n=6). G, 539 
Representative VCAM-1 and ICAM-1 immunostaining of aortic arch section (with arrows). 540 
Scale bars, 100 μm. *P<0.05, **P<0.01 and ***P<0.001 vs. LDLr-/- mice. #P<0.05, ##P<0.01 vs. 541 
STZ+HFD mice. ROS indicates reactive oxygen species; Nrf2, nuclear factor E2-related factor 542 
2; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1. 543 
Figure 3. Effects of H2S on diabetes-accelerated atherosclerosis in LDLr-/-Nrf2-/- mice. 544 
Diabetic LDLr-/-Nrf2-/- mice were fed a HFD and received daily ip injection of saline or 545 
GYY4137 (133 μmol/kg/day) for 4 weeks. A and B, Representative ORO and HE-staining 546 
images and quantification of aortic sinus sections from LDLr-/-Nrf2-/- mice, STZ+HFD and 547 
STZ+HFD+GYY4137 (n=5). Scale bars, 200 μm. C, Representative DHE fluorescence image 548 
of aorta. Scale bars, 100 μm. D, Quantification of DHE fluorescence image of C, *P<0.05, 549 
***P<0.001 vs. LDLr-/- mice, ##P<0.01, ###P<0.001 vs. LDLr-/-Nrf2-/- mice, n=5-7. E, 550 
Representative VCAM-1 and ICAM-1 immunostaining of aortic arch section (with arrows). 551 
Scale bars, 100 μm. F and G, mRNA levels of VCAM-1 and ICAM-1 in the aorta of LDLr-/-552 
Nrf2-/-, STZ+HFD and STZ+HFD+GYY4137 (n=5). H, mRNA levels of HO-1 in the aorta 553 
(n=5). Data shown are mean±SEM. *P<0.05, **P<0.01 vs. control. HO-1 indicates heme 554 
oxygenase-1.  555 
Figure 4. Effects of H2S on HG plus ox-LDL-treated primary peritoneal macrophages. 556 
Isolated peritoneal macrophages from C57BL/6 mice were treated with D-glucose (25 mM) 557 
plus ox-LDL (50 mg/L) in the presence or absence of GYY4137 (50 or 100 μM) for 24 h. A, 558 
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Macrophages incubated as above and stained with ORO. Scale bars, 20 μm. B, Representative 559 
DHE stained images showing ROS generation in each condition. Scale bars, 50 μm. C, 560 
Quantification of DHE fluorescence image of B, **P<0.01 vs. untreated control. #P<0.05, 561 
##P<0.01 vs. treatment with HG plus ox-LDL, n=5. D, Immunohistochemistry was performed 562 
on macrophages stained with antibody directed against Nrf2 (green) and DAPI (blue). Scale 563 
bars, 20 μm. E and F, Western blotting analysis and quantification of cytoplasmic and nuclear 564 
Nrf2 protein. GAPDH and histone H3 were used for normalization for cytoplasmic and nuclear 565 
proteins respectively (n=4). G, Western blotting analysis and quantification of HO-1 protein 566 
expression (n=4). Data shown are mean±SEM. *P<0.05, **P<0.01 and ***P<0.001 vs. untreated 567 
control. ##P<0.01 vs. treatment with HG plus ox-LDL.  568 
Figure 5. Effects of H2S on HG plus ox-LDL-treated primary peritoneal macrophages 569 
from Nrf2-/- mice. Isolated peritoneal macrophages from C57BL/6 (wild-type, WT) and Nrf2-570 
/- mice were treated with D-glucose (25 mM) plus ox-LDL (50 mg/L) in the presence or absence 571 
of GYY4137 (100 μM) for 24 h. A, macrophages from Nrf2-/- mice were stained with ORO. 572 
Scale bars, 20 μm. B, Representative DHE stained images of macrophages from WT and Nrf2-573 
/- mice. Scale bars, 50 μm. C, Quantification of DHE fluorescence image of B, ***P<0.001 vs. 574 
WT control. ###P<0.001 vs. WT with HG plus ox-LDL. &&&P<0.001 vs. Nrf2-/- control. n=3. D, 575 
Western blotting analysis and quantification of HO-1 protein expression in macrophages from 576 
Nrf2-/- mice (n=4). Data shown are mean±SEM. *P<0.05 vs. untreated control.  577 
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Figure 6. Effects of H2S on HG plus ox-LDL-treated endothelial cells. HUVECs were 578 
treated with D-glucose (25 mM) plus ox-LDL (50 mg/L) in the presence or absence of 579 
GYY4137 (50 or 100 μM) for 24 h. A, Representative DHE stained images showing ROS 580 
generation. Scale bars, 100 μm. B, Quantification of DHE fluorescence image of A, **P<0.01 581 
vs. untreated control. #P<0.05, ##P<0.01 vs.  treatment with HG plus ox-LDL. n=5. C, 582 
Immunohistochemistry was performed on HUVECs stained with antibody directed against 583 
Nrf2 (green) and DAPI (blue). Scale bars, 20 μm. D and E, Western blotting analysis and 584 
quantification of cytoplasmic and nuclear Nrf2 protein. GAPDH and histone H3 were used for 585 
normalization for cytoplasmic (n=5) and nuclear (n=4) proteins respectively. F and G, Western 586 
blotting analysis and quantification of VCAM-1 (n=4) and ICAM-1 (n=3) protein. H, mRNA 587 
levels of HO-1 (n=5). I, Western blotting analysis and quantification of HO-1 protein 588 
expression (n=4). Data shown are mean±SEM. *P<0.05, **P<0.01 and ***P<0.001 vs. untreated 589 
control. #P<0.05, ##P<0.01 and ###P<0.001 vs. treatment with D-glucose plus ox-LDL. HUVECs 590 
indicates human umbilical vein endothelial cells. 591 
Figure 7. Effects of H2S on HG plus ox-LDL-treated Nrf2 knockdown endothelial cells. 592 
EA.hy926 endothelial cells were transfected with control siRNA (Ctl siRNA) or Nrf2 siRNA 593 
for 24 h and then treated with D-glucose (25 mM) and ox-LDL (50 mg/L) in the presence or 594 
absence of GYY4137 (100 μM) for 24 h. A,  Western blotting analysis and quantification of 595 
Nrf2 (n=3). Data shown are mean±SEM. ***P<0.001 vs. Ctl siRNA control. B, Representative 596 
DHE staining images. Scale bars, 50 μm. C, Quantification of DHE fluorescence image of B, 597 
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**P<0.01, vs. Ctl siRNA control. #P<0.05 vs. Ctl siRNA with HG plus ox-LDL. &&&P<0.001 vs. 598 
Nrf2 siRNA control, n=5. 599 
Figure 8. H2S S-sulfhydrylated Keap1 at Cys151 to regulate Nrf2 transcription activity 600 
and reduce the generation of ROS in HG plus ox-LDL-treated endothelial cells. A, 601 
EA.hy926 endothelia cells were treated with GYY4137 (100 μM) followed by D-glucose (25 602 
mM) plus ox-LDL (50 mg/L) stimulation for 24 h, cell lysates were immunoprecipitated with 603 
an anti-Keap1 or an anti-IgG antibody (negative control), and blotted with an anti-Nrf2 604 
antibody (upper panel). An aliquot of total lysate was analyzed for Keap1, Nrf2 and GAPDH 605 
expression (lower panels). B, EA.hy926 endothelial cells were treated with DTT (1 mM, 606 
negative control）or D-glucose (25 mM) plus ox-LDL (50 mg/L) in the presence or absence of 607 
GYY4137 (100 μM) for 2 h. S-sulfhydration on Keap1 was detected with “Tag-Switch” method. 608 
C, After plasmid transfection of wild type Keap1(Keap1-WT) or mutated Keap1 at Cys151, 609 
Cys273, Cys288 for 24 h followed by GYY4137 (100 μM) treated for another 2 h, S-610 
sulfhydration on Keap1 was detected with “Tag-Switch” method. D, Transfected cells were 611 
treated with D-glucose (25 mM) plus ox-LDL (50 mg/L) in the presence or absence of 612 
GYY4137 (100 μM) for another 24 h, cell lysates immunoprecipitated with an anti-Keap1 613 
antibody and the immunoprecipitated proteins were subjected to immunoblot analysis with anti-614 
Nrf2 antibodies (upper panels). The total lysates was analyzed with anti-Keap1, anti-Nrf2, and 615 
anti-GAPDH antibodies (lower panels). E and F, Transfected cells treated with D-glucose (25 616 
mM) plus ox-LDL (50 mg/L) in the presence or absence of GYY4137 (100 μM) for 24h. 617 
 34 
   
Nuclear extracts prepared from cells were subjected to western blotting analysis for detecting 618 
the nuclear localization of Nrf2 (n=4). ROS accumulation was determined by the DHE assay. 619 
Scale bars, 50 μm. Data shown are mean±SEM. **P<0.01 vs. Keap1-WT transfected cells 620 
treatment with D-glucose plus ox-LDL. G, Quantification of DHE fluorescence image of F, 621 
**P<0.01 vs. untreated Keap1-WT transfected cells. ##P<0.01 vs. Keap1-WT transfected cells 622 
treated with D-glucose and ox-LDL. &&P<0.01 vs. untreated C151A transfected cells, n=4. 623 








